RESUMO
In the Samara oblast, cardiovascular diseases take the first place (53%) in the structure of total mortality. Due to the realization of the Federal program on improvement of medical care to patients with cardiovascular diseases, morbidity rates of acute blood circulation disorders decreased from 343 to 326 per 100 000, mortality rates decreased from 145,7 to 87,4 per 100 000 and percent of discharged patients who were independent in daily life increased from 50,8% in 2010 to 64,2% in 2012. Positive results of the organization of specialized care to stroke patients demand the implementation of this experience on the whole territory of the Samara oblast.
Assuntos
Atenção à Saúde/tendências , Gerenciamento Clínico , Programas Governamentais/tendências , Desenvolvimento de Programas , Melhoria de Qualidade/organização & administração , Acidente Vascular Cerebral/terapia , HumanosAssuntos
Neoplasias das Glândulas Suprarrenais/diagnóstico , Feocromocitoma/diagnóstico , Neoplasias das Glândulas Suprarrenais/patologia , Neoplasias das Glândulas Suprarrenais/cirurgia , Glândulas Suprarrenais/patologia , Adrenalectomia , Adulto , Feminino , Humanos , Masculino , Recidiva Local de Neoplasia/diagnóstico , Recidiva Local de Neoplasia/cirurgia , Feocromocitoma/patologia , Feocromocitoma/cirurgiaRESUMO
Thrombolytic activity of liposomal terrilytin forms has been experimentally studied. Liposomal terrilytin form (50-280 PU/kg) was administered to rabbits 24 hours after the experimental induction of femoral thrombi. In 43.75% of cases complete lysis of the thrombi was noted, in 37.5% of cases different stages of the lysis of wall thrombi were observed and in 18.75% of cases the thrombi remained. In the control experiments the thrombi remained in 75% of cases, while in 25% of cases spontaneous lysis of the thrombi occurred. Statistically significant hemostasis changes gave evidence of the decrease in the blood clotting activity after oral administration of a liposomal terrilytin form. It has become possible to achieve thrombolytic effect using lower doses of orally administered liposomal terrilytin form, which is both therapeutically and economically important.